Disease Information

Fanconi Anemia Explained

What Is FA?

FA is a genetic disease caused by mutations in any of the known 23 genes (including genes such as BRCA1 and BRCA2) that play a role in the FA DNA repair pathway. FA is considered a cancer-predisposition or cancer-susceptibility disease. Decades of research have revealed that faulty DNA repair causes FA, and individuals with FA are much more likely to develop cancer at a young age.

Learn More

Better Care Now

Clinical Care Guidelines

At Fanconi Cancer Foundation, we are in relentless pursuit of better care, better treatment, and ultimately, a cure for FA and FA-related cancers. Our clinical care guidelines are here as a resource for medical and care team providers who may never have crossed paths with FA before, in hopes they are able to provide better support for patients with FA.

Learn More

Knowledge Is Key

Cancer Awareness and Empowerment

Cancer can be daunting, and it’s natural to want to avoid dwelling on it. At FCF, we understand the weight of this concern for families affected by FA. That’s why we’re committed to partnering with the FA research and medical community to confront this challenge head-on. While experts work tirelessly towards solutions, we encourage you to stay informed without feeling overwhelmed.

Learn More

Stay Informed

Resource Library

Explore our library of educational materials and videos to empower individuals and families impacted by FA. Gain insights, guidance, and understanding to navigate FA’s complexities with more confidence.

Learn More

The Latest

News & Events

From Shock to Strength: Our FA Diagnosis

It took me weeks to come to terms with the fact that there were no easy answers. I couldn't change the past or the diagnosis, so I focused on educating myself and becoming Tinslee's biggest advocate. We underwent all the necessary tests, scans, and procedures, and spent a year going in for lab work and check-ups.

Fanconi Cancer Foundation Names Isis Sroka, PhD as CEO; Mark Quinlan Will Serve in Advisory Role Through a Transition Period

The Fanconi Cancer Foundation (FCF) is excited to announce that Dr. Isis Sroka has been named CEO effective August 1, 2024. She succeeds Mark Quinlan who served as Executive Director since 2017 and recently announced his departure. Quinlan will continue in an advisory role with FCF through a transition period.

FA Europe Meeting Unites Physicians, Researchers and Advocates in Paris

On May 24th, 2024, the FA Europe Network hosted its inaugural pan-European scientific meeting at the historic Saint-Louis Hospital in Paris, marking a significant milestone in international collaboration for Fanconi anemia (FA).